baber/WOPTO huggingface dataset:
Patent NZ-513528-A (NZ)
Title: Telmisartan polymorphs and their use as angiotensin antagonists
Inventor: SCHNEIDER HEINRICH
IPC: A61K31/4184
Filed: 2000-01-07
Abstract: Polymorphic crystal modification B of telmisartan (formula I), where an endothermic maximum at 183 2oC occurs during thermal analysis using DSC. The polymorphic crystal modification B of telmisartan is useful for the treatment of hypertension and cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), diabetic neuropathy, glaucoma, gastrointestinal diseases and bladder diseases and in the prevention of the progression of cardiac insufficiency after myocardial infarction.
Patent NZ-514554-A (NZ)
Title: NR2B subunit selective NMDA receptor antagonists for treatment of depression, hearing and vision loss, and neurological damage
Inventor: CHENARD BERTRAND LEO
IPC: A61P27/16
Filed: 2001-10-01
Abstract: Use of NR2B subunit selective NMDA antagonists for treating certain disorders resulting from neurodegeneration and for treating depression is disclosed. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
Patent NZ-515895-A (NZ)
Title: Gyratory or cone crusher with continuous stroke adjustment ability
Inventor: SAVOLAINEN REIJO
IPC: B02C2/04
Filed: 2000-06-15
Abstract: The main shaft 1, of a crusher, is placed into a bore of a rotatable eccentric shaft 4. The main shaft 1 has a central axis, A which is inclined in respect of the axis of rotation B of the eccentric shaft 4, and a first crushing head 2.  The first crushing head 2 is attached to and rotated by the main shaft 1, in respect of a second crushing head 3. The inclination of the central axis A of the main shaft 1 can be changed in respect of the axis of rotation B of the eccentric shaft 4 allowing a change in magnitude of constrained stroke motion.  Constrained stroke motion is effected between the first crushing head 2, and the second crushing head 3.
Patent NZ-516336-A (NZ)
Title: Thiophene A2A receptor agonists
Inventor: ZABLOCKI JEFF A
IPC: A61P9/00
Filed: 2000-06-20
Abstract: 2-Adenosine thiophene compounds having the formula (I): and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Patent NZ-518186-A (NZ)
Title: Method and means for detecting inflammatory processes such as ulcerative colitis, Crohn's disease and celiac disease using nitrogen isotope labled peptides
Inventor: PETTERSSON ANDERS
IPC: G01N33/50
Filed: 2000-10-24
Abstract: A method of detecting inflammatory processes, such as ulcerative colitis, celiac disease, or Crohn's disease, comprising: (a) Administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido- 15N2]-arginine, L-[guanido15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) Collecting a sample of exhaled air, saliva or urine; (c) Determining 15N in the air sample or its transformation products 15N -nitrite and/or 15N -nitrate in the saliva sample or urine. Also disclosed is a corresponding diagnostic composition for use in diagnosing inflammatory processes and a method for its manufacture.
Patent NZ-523313-A (NZ)
Title: Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Inventor: BANDO TAKUJI
Filed: 2002-09-25
Abstract: Hydrate A of aripiprazole where the hydrate has: - a powder x-ray diffraction spectrum which is the same as the following powder x-ray diffraction spectrum as disclosed; - particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm-1 on the IR (KBr) spectrum; - an endothermic curve which is the same as the thermogravimetric/differential thermal analysis (heating rate 5oC/min) endothermic curve as disclosed; and - a mean particle size of 50 mm or less.
Patent NZ-525449-A (NZ)
Title: Novelty cap having fan-like structure
Inventor: FLEMING WARD
IPC: A45B11/02
Filed: 2001-02-23
Abstract: A novelty cap is provided having a strip of fabric with an accordion folding defined by a plurality of pleated fin-like members (34). The strip can be made to close or open to a fan-like structure while mounted on top of the head of a wearer. The rearmost fin is weighted, i.e., comprises a metal bar (16), which serves to keep the fan-like structure in fully opened position.
Patent NZ-536336-A (NZ)
Title: Method and system for transmitting notifications to users of a logistic system
Inventor: MAYER BORIS
Filed: 2003-08-06
Abstract: A method and device for transmitting notifications to users of a logistic system where the logistic system has one or more parcel component systems with one or more registered users is disclosed. The notification orders are transmitted to a central sending component 30 which generates appropriate notifications and sends them to the users. To generate these notifications the central sending component accesses databases 70, 80, 90 where different modules with associated functions are called up in each case and the modules generate notifications that have their status validated 20 before being transferred to the central sending component for immediate or deferred sending.
Patent NZ-541297-A (NZ)
Title: Combination therapy of ZD6474 with 5-FU or/and CPT-11
Inventor: WEDGE STEPHEN ROBERT
IPC: A61P35/00
Filed: 2004-02-11
Abstract: Disclosed is a synergistic combination of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4ylmethoxy)quinazoline, also known as ZD6474, and one or both of 5-fluorouracil and irinotecan. The combination is useful in the treatment of cancer.
Patent NZ-542276-A (NZ)
Title: Synergistically acting herbicidal mixtures
Inventor: ZAGAR CYRILL
IPC: A01N43/90
Filed: 2004-03-12
Abstract: Disclosed is a synergistic herbicidal mixture comprising (A) picolinafen or one of its environmentally compatible salts; and (B) a synergistically effective amount of at least a triazolopyrimidine herbicide selected from the triazolopyrimidine sulfonanilides and penoxsulam or one of its environmentally compatible salts or esters; and, if desired, (C) at least a safener. Compositions comprising these mixtures, processes for the preparation of these compositions and their use for controlling undesired plants are also disclosed.
Patent NZ-543192-A (NZ)
Title: Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
Inventor: BRINES MICHAEL
IPC: G01N33/68
Filed: 2004-04-26
Abstract: Disclosed are methods for identifying compounds that have a tissue protective activity using a hetero-multimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one betac receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.
Patent NZ-547377-A (NZ)
Title: Analgesic compounds from plants, extracts containing same and methods of preparation
Inventor: QUINN RONALD
IPC: C07H15/256
Filed: 2004-11-26
Abstract: Disclosed are compounds of formula (I) that are obtained from plants of the Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at the 21 position which may optionally be further substituted with benzoyl, dibenzoyl, methyl butanoyl, methyl butyryl or tigloyl at the 3 or 4 positions. Alternatively at the 21 position there is provided tigloyl, benzoyl or dibenzoyl substituents.
Patent NZ-552870-A (NZ)
Title: Tripod assembly with legs at least partially enclosing base and head in closed position
Inventor: MURRAY CHRISTOPHER J
IPC: F16M11/28
Filed: 2004-11-01
Abstract: A tripod assembly is disclosed having a base and a head mounted to the base. A plurality of legs are coupled to the base and are moveable between an open position and a closed position. The plurality of legs form a tripod to support the base and head in an upright position when the legs are in the open position. The plurality of legs at least partially enclose the base and the head when in the closed position.
Patent NZ-555134-A (NZ)
Title: Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
Inventor: KANWAR JAGAT RAKESH
IPC: A23L1/305
Filed: 2005-11-18
Abstract: Provided is the use of metal ion-saturated lactoferrin or a metal ion-saturated functional variant or fragment thereof in the manufacture of a composition for increasing the responsiveness of a subject to a cancer therapy. Metal ion can be iron. Specific diseases to be treated are recited, as well as specific levels of ion saturation.
Patent NZ-556769-A (NZ)
Title: Use of ionic liquids for extraction or fractionation of lipids
Inventor: ELTRINGHAM WAYNE
IPC: C07C29/74
Filed: 2007-07-27
Abstract: Disclosed is a process for separating one or more unsaturated lipids from a feed material, comprising at least the steps of: (i) contacting the feed material with an ionic liquid phase to give an ionic liquid phase containing one or more unsaturated lipids; and a raffinate; (ii) separating the ionic liquid phase containing one or more unsaturated lipids from the raffinate; and (iii) recovering one or more unsaturated lipids from the ionic liquid phase containing one or more unsaturated lipids. Also disclosed is a process for separating one or more unsaturated lipids from a feed material, comprising at least the steps of: (i) contacting the feed material with a near-critical fluid to give a near-critical solution containing one or more unsaturated lipids; and a raffinate; (ii) separating the near-critical solution from the raffinate; (iii) contacting the near-critical solution with an ionic liquid phase to give: an ionic liquid phase containing one or more unsaturated lipids; and a lipid-depleted near-critical fluid phase; (iv) separating the ionic liquid phase containing one or more unsaturated lipids from the lipid-depleted near-critical fluid phase; and (v) recovering the one or more unsaturated lipids from the ionic liquid phase containing one or more unsaturated lipids.
Patent NZ-570935-A (NZ)
Title: A thermometer
Inventor: JOSEPHSON GRAEME NEAL
Filed: 2008-09-02
Abstract: A thermometer that can be secured to the exterior of a glass pane forming part of a window of a building is disclosed. The thermometer has a temperature display, a contact portion and a support arm cantilevered from the contact portion, and the contact portion has a suction surface to engage the glass. The display can be read from inside the building, through the glass pane.
Patent NZ-572763-A (NZ)
Title: Aziridinyl-epothilone compounds
Inventor: KIM SOONG-HOON
IPC: A61K31/396
Filed: 2007-05-25
Abstract: Disclosed are aziridinyl epothilone compounds having Formula (X) and pharmaceutically acceptable salts and solvates thereof, wherein K is -O-, -S- or -NR7- and the remaining substituents are as defined in the specification. The compounds can be used in cancer treatment of for the preparation of conjugates for targeted drug delivery, especially folates.
Patent NZ-583607-A (NZ)
Title: Valomaciclovir polymorphs
Inventor: O'NEILL MIKE H
IPC: A61K31/52
Filed: 2008-09-18
Abstract: The disclosure relates to crystalline valomaciclovir having characteristic absorption peaks at 22.9 deg. +/- 0.2 deg., 18.6 deg. +/- 0.2 deg., 19.5 deg. +/- 0.2 deg., 24.3 deg. +/- 0.2 deg., 20.8 deg. +/- 0.2 deg., 21.8 deg. +/- 0.2 deg., 27.0 deg. +/- 0.2 deg., 14.7 deg. +/- 0.2 deg., 15.5 deg. +/- 0.2 deg., 25.5 deg. +/- 0.2 deg., and 29.9 deg. +/- 0.2 deg. in an X-ray powder diffractogram. The disclosure also relates to pharmaceutically acceptable salt of valomaciclovir which possesses the desired pharmacological activity of the parent compound and is suitable for the treatment or prevention of a viral infection selected from varicella zoster virus, herpes simplex viruses (HSV-1 and HSV-2), human herpes viruses (HHV-6, HHV-7 and HHV-8), Epstein Barr virus, cytomegalovirus, and HIV infection. The disclosure further relates to a process of preparing crystalline valomaciclovir, comprising the steps of: (a) dissolving valomaciclovir in a lower alkanol solvent or a mixed solvent of lower alkanols by heating to an appropriate internal temperature; (b) cooling the solution with stirring to effect substantial crystallization of valomaciclovir; and(c) collecting the crystalline valomaciclovir.
Patent NZ-586423-A (NZ)
Title: Liver function-protecting agent comprising a phospholipid
Inventor: ISOGAI TOMOYUKI
IPC: A61K31/683
Filed: 2009-01-15
Abstract: Disclosed is a liver function-protecting agent comprising (1) phospholipid in an amount of 10 wt% or more based on the total solid content of the composition, and (2) lactosylceramide in an amount of 0.16 wt% or more based on the total solid content of the composition, wherein the lactosylceramide is obtained by heating milk or milk material under acidic conditions.
Patent NZ-587907-A (NZ)
Title: Quinazoline derivatives as RAF kinase modulators and methods of use thereof
Inventor: ABRAHAM SUNNY
IPC: A61K31/517
Filed: 2009-03-17
Abstract: The disclosure relates to quinazoline derivative compounds represented by formulae (VA) & (VB) and compositions thereof, wherein the variables are as defined in the specifications. The compounds are suitable for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases, thereby making them useful for treating a cancer selected form melanoma, papillary thyroid carcinoma, colorectal, ovarian, breast cancer, endometrial cancer, liver cancer, sarcoma, stomach cancer, Barret's adenocarcinoma, glioma, small cell lung cancer, non small cell lung cancer, head and neck cancer, acute lymphoblastic leukemia or non-Hodgkin's lymphoma; these compounds are also useful for treating inflammatory disease selected form immune dysfunction, immunodeficiency, immunomodulation, autoimmune disease, tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease, multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, allergic rhinitis, inflammatory bowel disease, systemic lupus erythematosis, arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma or chronic obstructive pulmonary disease.
Patent NZ-588324-A (NZ)
Title: Perfusion and/or preservation solution containing peptide inhibitors of protein kinase c beta 2 and/or protein kinase c zeta and/or peptide activators of protein kinase c delta for organs
Inventor: YOUNG LINDON H
IPC: C12N5/071
Filed: 2006-01-13
Abstract: Discloses a solution when used for perfusion, preservation, or re-perfusion for organ preservation comprising at least peptide inhibitor of protein kinase C æ (PKC æ) or Gö 6983 as an inhibitor of PKC æ, where said organ is a human organ external to and isolated from a human body or a non-human organ. Further disclosed are optional components of the claimed solution which comprise: at least one myristoylated or non- myristoylated peptide inhibitor of PKCz at about 2.5-5mM, at least one myristoylated or non- myristoylated peptide activator of PKC d at about 5-10mM, a saline solution and/or potassium chloride. Further provided are methods for perfusion, preservation, or re-perfusion of an organ using the claimed solution. Also provided are uses of the solution comprising at least one peptide inhibitor of PKCz or Gö56983 as an inhibitor of PKCz for the preparation of a perfusion or preservation solution for an organ of human origin. The said organ is located in a human patient prior to transplantation, in an organ suffering from ischemia, or after isolation from the circulatory system.
Patent NZ-593916-A (NZ)
Title: Uses of thaxtomin and thaxtomin compositions as herbicides
Inventor: KOIVUNEN MARJA
IPC: A01N35/06
Filed: 2009-12-30
Abstract: 593916 Disclosed is a method for modulating germination and growth of monocotyledonous, dicotyledonous and sedge weeds in a non-rice cereal crop growth system and/or a turf grass growth system and/or Timothy grass growth system and/or pasture grass growth system, comprising applying to said weeds or soil in said growth system at least one herbicidal agent, wherein said herbicidal agent is thaxtomin. Additionally disclosed is a herbicidal composition comprising thaxtomin and a second herbicide selected from a bioherbicide or chemical herbicide, and the use thereof.
Patent NZ-596764-A (NZ)
Title: N-glycan core beta-galactosyltransferase and uses thereof
Inventor: KUNZLER MARKUS
IPC: C07K1/14
Filed: 2010-05-28
Abstract: 596764 Disclosed is an isolated and purified nucleic acid, wherein said nucleic acid is selected from the group consisting of: (i) a nucleic acid comprising at least a nucleic acid sequence selected from the group consisting of nucleic acid sequences listed in SEQ ID NOs: 1, 3, 5, 7 and 9; (ii) a nucleic acid having a sequence of at least 70, at least 80, at least 90, at least 95 or at least 98 % identity with the nucleic acid sequence listed in SEQ ID NO 1; (iii) a nucleic acid that hybridizes to a nucleic acid of (i) or (ii) under stringent conditions; (iv) a nucleic acid, wherein said nucleic acid is derivable by substitution, addition and/or deletion of one of the nucleic acids of (i), (ii) oder (iii); (v) a functional fragment of any of the nucleic acids of (i) to (iv), that hybridizes to a nucleic acid of (i) under stringent conditions, wherein the nucleic acids of (iii) to (v) encode a protein having galactosyltransferase activity. Further disclosed is an isolated and purified polypeptide selected from the group consisting of: (a) polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8 and 10, preferably SEQ ID NO: 2, (b) polypeptides encoded by a nucleic acid of any of claims 1 to 3, (c) polypeptides having an amino acid sequence identity of at least 70, at least 80, at least 90 or at least 95 % with the polypeptides of (a) and/or (b) having galactosyltransferase activity, (d) a functional fragment and/or functional derivative of (a), (b) or (c) having galactosyltransferase activity.
Patent NZ-597644-A (NZ)
Title: N1-sulfonyl-5-fluoropyrimidinone derivatives
Inventor: BOEBEL TIMOTHY
IPC: A01N43/54
Filed: 2010-08-05
Abstract: Disclosed are 4-amino-1-(benzenesulfonyl)-5-fluoro-1H-pyrimidin-2-one derivatives as represented by the general formula (I), wherein R1 and R2 are as defined herein and R3 is -SO2R14; where R14 is alkyl, haloalkyl, amino, alkylamino, dialkylamino, optionally substituted phenyl, optionally substituted benzyl, 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yloxy)-3-methylphenyl, 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yloxy)-2-methylphenyl, or an optionally substituted 5- or 6-membered saturated or unsaturated ring containing 1-3 heteroatoms. Representarive compounds include N’-(1-benzenesulfonyl-5-fluoro-2-oxo-1,2-dihydro-pyrimidin-4-yl)-N,N-dimethylformamidine, 4-chloro-N-[1-(4-chlorobenzenesulfonyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]benzamide, N’-[5-fluoro-1-(1-methyl-1H-imidazole-4-sulfonyl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-N,N-dimethylformamidine, 1-(1-benzenesulfonyl-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)-3-phenylurea, (1-benzenesulfonyl-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)-3-phenylthiourea, (1-benzenesulfonyl-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamic acid phenyl ester, 4-amino-1-(methylsulfonyl)-5-fluoro-1H-pyrimidin-2-one and N’-(1-thiophen-2-ylsulfonyl-5-fluoro-2-oxo-1,2-dihydro-pyrimidin-4-yl)-N,N-dimethylformamidine. Also disclosed is a method for the control and prevention of fungal attack on a plant, the method including the steps of: applying a fungicidally effective amount of at least one of the compounds as defined above to at least one of the plant, an area adjacent to the plant, soil adapted to support growth of the plant, a root of the plant, foliage of the plant, and a seed adapted to produce the plant.
Patent NZ-597737-A (NZ)
Title: Machine for packaging products in rigid or semirigid trays sealed across the top by a thermoplastic film, particularly for producing packs in a modified atmosphere
Inventor: VACCARI MASSIMILIANO
IPC: B65B7/16
Filed: 2010-08-03
Abstract: 597737 Disclosed is a packing machine for packaging products in rigid or semi-rigid trays sealed across the top by a thermoplastic film, for producing packs with a modified or non-modified atmosphere and having an intermittent operation. The machine comprises a first station for preparing groups of product-filled trays arranged with the correct mutual spacing in one or two parallel rows. An intermediate station closes and heat-seals a cover onto the top edge of the groups of trays, optionally after removing the air from the trays and/or replacing the air with a modified atmosphere useful for the preservation of the packaged products and with a subsequent cutting operation to separate the closed trays from the continuous web from which the closing cover is taken. A final station discharges the groups of trays with the packaged product. The machine also cyclically and simultaneously transfers the groups of trays with the product from the first station to the second station and from this second station to the third and final or discharging station. The stations are equidistant from each other in the horizontal direction and the transfer means comprise moving and lifting combs that operate alongside the stations. The lifting combs move or transfer the groups of the row or rows of trays, without substantially interfering with them from one station to the station immediately following. Each of the lifting combs is connected to three relative means for synchronized motion along three orthogonal axes and in particular along an X axis for horizontal movements towards and away from the groups of trays, a Y axis for horizontal movements for the transfer of trays from one station to the next and for the subsequent return-to-rest movement, and a vertical Z axis for lifting and lowering movements.
Patent NZ-598464-A (NZ)
Title: Methods and compositions for treatment of pulmonary fibrotic disorders
Inventor: SPANGLER RHYANNON
IPC: A61K39/00
Filed: 2010-08-20
Abstract: Disclosed is the use of an isolated lysyl oxidase-related-2 (LOXL2) inhibitor in the manufacture of a medicament for the prevention of, treatment of, or reversing a symptom of a pulmonary fibrotic disorder in a subject, wherein the inhibitor is an antibody that specifically binds to a LOXL2 protein, and prevents an increase in or decreases pulmonary leukocyte number in the subject.
Patent NZ-600348-A (NZ)
Title: Anti-c5a binding moieties with high blocking activity
Inventor: RIEDEMANN NIELS CHRISTOPH
IPC: C07K16/18
Filed: 2010-11-26
Abstract: NZ 600348 Disclosed is a binding moiety which binds to a conformational epitope formed by amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of C5a, wherein the binding moiety binds to at least one amino acid within the amino acid sequence according to SEQ ID NO: 2 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 3; wherein said binding moiety has a binding constant to C5a with a Kd value of 100 nM or less; wherein said binding moiety is selected from the group consisting of: (a) antibodies or antigen-binding fragments thereof; and (b) antibody-like proteins.